What Is 5-Amino-1MQ? The Small Molecule Built to Switch Off NNMT

Every cell runs two quiet economies at once. One trades in NAD+, the molecule that powers metabolism and DNA repair. The other trades in methyl groups — the small chemical tags, carried by a currency called SAM, that switch genes and proteins on and off. For decades, one enzyme has sat at the till of both, charging a toll nobody asked it to. Its name is NNMT, and 5-Amino-1MQ is a small molecule built for one purpose: to switch the toll booth off.

It is worth saying plainly, before anything else, what this compound is and is not. 5-Amino-1MQ — full name 5-amino-1-methylquinolinium — is a small molecule, not a peptide. It belongs to a different chemical family entirely from the peptides that dominate metabolic research conversations, such as retatrutide. Yet it has become one of the most discussed metabolic research compounds of the decade, and the reason lies in the strange double role of the enzyme it targets.

What is NNMT, and why would you want to inhibit it?

NNMT stands for nicotinamide N-methyltransferase. Its job, on paper, sounds harmless: it takes nicotinamide — a B-vitamin form and a direct precursor to NAD+ — and attaches a methyl group to it, producing a waste product called 1-methylnicotinamide. To do that, it spends a methyl group from SAM (S-adenosylmethionine), the cell’s universal methyl donor.⁵

Look at that reaction twice and the problem appears. Every time NNMT fires, it consumes a NAD+ precursor and burns a unit of methylation currency. In tissues where NNMT is quietly overexpressed — and white fat is one of them — this becomes a chronic drain on two economies at once. The enzyme behaves like a leak in the plumbing: not dramatic in any single moment, but expensive over time. The idea behind inhibiting it is simple. Close the leak, and the cell keeps more of its own NAD+ and more of its own methyl groups.¹²⁵

Where did the idea come from?

The compound did not arrive first. The hypothesis did. In 2014, a study in Nature took the genetic route: rather than block NNMT with a drug, the researchers knocked down the gene itself in mice. The animals were then fed a high-fat diet. The result was striking enough to launch the entire field — mice with reduced NNMT were protected against diet-induced obesity, with measurable shifts in their fat-cell metabolism.²

That finding posed an obvious question. If silencing the gene helps, could a small molecule that silences the enzyme do the same — without genetic engineering? In 2018, a team answered it. They designed selective, membrane-permeable small-molecule NNMT inhibitors — 5-Amino-1MQ among them — and reported that these compounds reversed high-fat-diet-induced obesity in mice.¹ Membrane permeability matters here: the enzyme works inside the cell, so a useful inhibitor has to get in. That, in a sentence, is why 5-Amino-1MQ exists as a research tool rather than a footnote.

What has actually been observed in the lab?

Two layers of evidence sit underneath this compound, and it helps to keep them separate. The first is cellular. In differentiating pre-adipocytes — immature fat cells caught in the act of maturing and filling with lipid — NNMT inhibition reduced lipogenesis (the building of new fat) in a concentration-dependent way. The micromolar concentrations applied to those cells are reported here strictly as the quantities used in that in-vitro system, never as guidance for any person.¹⁵

The second layer is the whole animal. In diet-induced-obese (DIO) mice, membrane-permeable NNMT inhibitors reversed the weight gained on a high-fat diet.¹ Later work extended the picture: NNMT inhibition mitigated obesity-related metabolic dysfunction in mouse models,³ and one 2022 study found that pairing a reduced-calorie diet with NNMT inhibition established a distinct gut microbiome in DIO mice — a hint that the enzyme’s reach extends beyond the fat cell itself.⁴ Again, the milligram-per-kilogram doses in these studies are the figures used in those mouse experiments, attributed to them and to nothing else.

The NNMT pathway at a glance: what the enzyme does versus what blocking it was observed to do, in cell and mouse models. Figures and effects belong strictly to those preclinical systems.

How strong is the human evidence, really?

Here is where intellectual honesty matters more than enthusiasm. The case for 5-Amino-1MQ is elegant, mechanistically coherent, and supported by genuinely interesting genetics and pharmacology. It is also, as of 2026, entirely preclinical. Every result described above comes from cultured cells or from mice — the diet-induced-obese mouse being the workhorse model throughout.¹²³⁴

There is no FDA-approved indication for 5-Amino-1MQ. There is no registered human clinical trial. That gap is not a footnote — it is the most important fact in this article. The history of metabolism research is full of compounds that protected mice and disappointed people, because the mouse is not a small human and a high-fat-diet model is not the lived complexity of human metabolic disease. The NAD+ and SAM signals are real and reproducible in the systems studied; what they mean for any organism more complicated than a mouse is, at present, simply unknown. A responsible reading of the literature treats 5-Amino-1MQ as a promising mechanistic probe — a way to ask what NNMT does — not as a settled answer to anything.

What is 5-Amino-1MQ used for in research?

As a research material, the appeal is precisely that mechanistic clarity. NNMT sits at an unusual intersection of NAD+ biology, methylation, adipocyte function and longevity hypotheses, which means a clean, membrane-permeable inhibitor is a useful instrument for laboratories probing any of those threads. It lets researchers move from correlation (NNMT is high in this tissue) toward causation (block it and see what changes). That is the legitimate scientific role of a tool compound — and the only role we describe.

Why does material identity and purity matter here?

For a small molecule defined by a single enzymatic interaction, identity is everything. A compound sold under the name 5-Amino-1MQ is only useful to a laboratory if it is, in fact, 5-amino-1-methylquinolinium — correctly synthesised, characterised and free of confounding contaminants that could muddy a NAD+ or lipogenesis readout. This is where a Certificate of Analysis (COA) stops being paperwork and becomes part of the science: it documents identity and purity so that an experimental result reflects the molecule, not its impurities.

Condor Research supplies 5-Amino-1MQ strictly as a Research Use Only (RUO) material. It is not a medicine, not a dietary supplement, and not for human or veterinary use. Every dose and concentration cited above belongs to a published cell or animal study and is reported as a scientific figure only — never as an instruction, protocol or recommendation for a person. The honest summary is the one the data supports: an enzyme worth understanding, a tool built to interrogate it, and a body of work that, for now, lives entirely in cells and in mice.